Monte Rosa Therapeutics Inc
GLUE19.550USD
+0.650+3.44%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.21BMarket Cap
61.50P/E TTM
More Details of Monte Rosa Therapeutics Inc Company
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Monte Rosa Therapeutics Inc Info
Ticker SymbolGLUE
Company nameMonte Rosa Therapeutics Inc
IPO dateJun 24, 2021
CEOWarmuth (Markus)
Number of employees134
Security typeOrdinary Share
Fiscal year-endJun 24
Address321 Harrison Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02118
Phone16179492643
Websitehttps://www.monterosatx.com/
Ticker SymbolGLUE
IPO dateJun 24, 2021
CEOWarmuth (Markus)
Company Executives of Monte Rosa Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.84K
+31845.00%
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
62.37K
+32371.00%
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
37.03K
+27845.00%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
24.84K
+24845.00%
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Chandra P. Leo, M.D.
Dr. Chandra P. Leo, M.D.
Independent Director
Independent Director
--
--
Ms. Christine Siu
Ms. Christine Siu
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.84K
+31845.00%
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
62.37K
+32371.00%
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
37.03K
+27845.00%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
24.84K
+24845.00%
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 18
Updated: Sun, Jan 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
10.55%
Dimension Management, L.P.
7.77%
BVF Partners L.P.
7.76%
Baker Bros. Advisors LP
6.74%
T. Rowe Price Associates, Inc.
6.23%
Other
60.95%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
10.55%
Dimension Management, L.P.
7.77%
BVF Partners L.P.
7.76%
Baker Bros. Advisors LP
6.74%
T. Rowe Price Associates, Inc.
6.23%
Other
60.95%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.56%
Venture Capital
24.85%
Hedge Fund
23.18%
Investment Advisor/Hedge Fund
12.40%
Research Firm
1.63%
Individual Investor
0.98%
Pension Fund
0.16%
Family Office
0.08%
Bank and Trust
0.08%
Other
5.09%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
254
70.21M
97.11%
+1.07M
2025Q3
233
66.43M
102.01%
+1.24M
2025Q2
232
62.74M
101.99%
-2.45M
2025Q1
235
60.82M
98.88%
-7.09M
2024Q4
220
61.73M
100.63%
-766.83K
2024Q3
200
57.64M
94.07%
-4.29M
2024Q2
191
55.42M
93.92%
+8.23M
2024Q1
185
49.41M
98.58%
+2.43M
2023Q4
187
49.83M
99.64%
+961.54K
2023Q3
187
51.89M
104.49%
+4.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
7.69M
11.81%
--
--
Sep 30, 2025
Dimension Management, L.P.
4.76M
7.31%
+4.76M
--
May 16, 2025
BVF Partners L.P.
5.66M
8.69%
--
--
Sep 30, 2025
Baker Bros. Advisors LP
4.92M
7.55%
--
--
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.54M
6.98%
-1.69M
-27.09%
Sep 30, 2025
TCG Crossover Management, LLC
4.43M
6.8%
+4.43M
--
Oct 10, 2025
Suvretta Capital Management, LLC
3.36M
5.16%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.30M
5.07%
-55.09K
-1.64%
Sep 30, 2025
Versant Ventures
4.91M
7.54%
-744.80K
-13.18%
Nov 10, 2025
The Vanguard Group, Inc.
2.99M
4.59%
-151.56K
-4.83%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.77%
Royce Quant Small-Cap Quality Value ETF
0.47%
iShares Micro-Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Avantis US Small Cap Equity ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Russell 2000 Value ETF
0.05%
iShares Biotechnology ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
ProShares Hedge Replication ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.77%
Royce Quant Small-Cap Quality Value ETF
Proportion0.47%
iShares Micro-Cap ETF
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Avantis US Small Cap Equity ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Russell 2000 Value ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.04%
ProShares Hedge Replication ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
